| Literature DB >> 27891252 |
Tamara J Somers1, Sarah A Kelleher1, Kelly W Westbrook2, Gretchen G Kimmick2, Rebecca A Shelby1, Amy P Abernethy3, Francis J Keefe1.
Abstract
Psychosocial pain management interventions are efficacious for cancer pain but are underutilized. Recent advances in mobile health (mHealth) technologies provide new opportunities to decrease barriers to access psychosocial pain management interventions. The objective of this study was to gain information about the accessibility and efficacy of mobile pain coping skills training (mPCST) intervention delivered to cancer patients with pain compared to traditional in-person pain coping skills training intervention. This study randomly assigned participants (N = 30) to receive either mobile health pain coping skills training intervention delivered via Skype or traditional pain coping skills training delivered face-to-face (PCST-trad). This pilot trial suggests that mPCST is feasible, presents low burden to patients, may lead to high patient engagement, and appears to be acceptable to patients. Cancer patients with pain in the mPCST group reported decreases in pain severity and physical symptoms as well as increases in self-efficacy for pain management that were comparable to changes in the PCST-trad group (p's < 0.05). These findings suggest that mPCST, which is a highly accessible intervention, may provide benefits similar to an in-person intervention and shows promise for being feasible, acceptable, and engaging to cancer patients with pain.Entities:
Year: 2016 PMID: 27891252 PMCID: PMC5116348 DOI: 10.1155/2016/2473629
Source DB: PubMed Journal: Pain Res Treat ISSN: 2090-1542
Figure 1Baseline demographic and medical data (N = 30).
| M | SD | % |
| |
|---|---|---|---|---|
| Age | 60 | 11 | ||
| Gender-female | 50% | 15 | ||
| Marital status | ||||
| Single, widowed, divorced | 21% | 8 | ||
| Married/life partner | 79% | 22 | ||
| Education | ||||
| Less than high school | 3% | 1 | ||
| High school diploma | 14% | 4 | ||
| Some college | 21% | 6 | ||
| Bachelor's degree or higher | 62% | 18 | ||
| Race | ||||
| White | 97% | 29 | ||
| Black | 3% | 1 | ||
| Cancer type | ||||
| Breast | 23% | 7 | ||
| Lung | 23% | 7 | ||
| Prostate | 46% | 13 | ||
| Colorectal | 11% | 3 | ||
| Time since initial diagnosis (months) | 41 | 55 | ||
| Stage at study entry | ||||
| 0 | 3% | 1 | ||
| 1 | 13% | 4 | ||
| 2 | 17% | 5 | ||
| 3 | 27% | 8 | ||
| 4 | 40% | 12 | ||
| Comorbid disordersa | ||||
| Hypertension | 39% | 11 | ||
| Heart disease | 14% | 4 | ||
| Rheumatoid arthritis | 4% | 1 | ||
| Osteoarthritis | 21% | 6 | ||
| Diabetes | 21% | 6 | ||
| Sciatica | 8% | 2 | ||
| Emphysema, asthma, COPD | 31% | 8 | ||
| Crohn's disease or irritable bowel syndrome | 4% | 1 | ||
| Cancer treatments in last weekb | ||||
| Chemotherapy | 40% | 11 | ||
| Radiation | 11% | 3 | ||
| Surgery | 0% | 0 | ||
| Hormone therapy | 30% | 8 | ||
| Vaccine | 4% | 1 | ||
| Patient reported cancer therapy | 28% | 8 |
Note. a10 participants reported more than one comorbid disorder; b7 participants reported two or more treatments in the last week.
Correlations between demographic and medical variables and study outcome variables at baseline.
| Age | Gender | Marital | Education | Race | Time diagnosed | Cancer stage | Comorbid disorders | |
|---|---|---|---|---|---|---|---|---|
| Pain intensity | −.43 | .20 | .01 | −.24 | −.01 | −.16 | .21 | .30 |
| Pain catastrophizing | −.29 | .12 | .27 | .04 | .21 | −.02 | .33 | .36 |
| Pain self-efficacy | .21 | .06 | .03 | .07 | .04 | .07 | −.05 | −.02 |
| Physical functioning | −.28 | .02 | .15 | .17 | −.13 | −.16 | .14 | −.01 |
| Physical symptoms | −.01 | .14 | −.14 | −.08 | .10 | −.20 | −.15 | .26 |
| Distress | −.23 | .49 | −.11 | −.21 | .21 | −.12 | −.13 | .05 |
| Despair | −.13 | .12 | .05 | −.11 | .44 | .12 | .38 | .40 |
Note. p < 0.05 and p < 0.01; gender code: 0 = male and 1 = female; marital code: 0 = not partnered and 1 = partnered; and race code: 0 = White and 1 = African American.
Comparative pre- and postintervention data (N = 23).
| Before intervention | After intervention | |||
|---|---|---|---|---|
| M | SD | M | SD | |
| Pain intensity | ||||
| Full group | 4.19 | 1.86 | 2.68 | 1.98 |
| mHealth | 4.53 | 2.12 | 3.32 | 1.89 |
| In person | 3.86 | 1.61 | 2.05 | 1.95 |
| Pain catastrophizing | ||||
| Full group | 1.89 | 1.13 | 1.01 | 0.96 |
| mHealth | 1.64 | 1.33 | 1.42 | 0.99 |
| In person | 2.13 | 0.91 | 0.60 | 0.77 |
| Pain self-efficacy | ||||
| Full group | 48.76 | 18.40 | 60.32 | 27.81 |
| mHealth | 46.00 | 20.51 | 51.45 | 25.78 |
| In person | 51.30 | 16.72 | 68.44 | 28.16 |
| Physical functioning | ||||
| Full group | 5.08 | 2.37 | 3.94 | 2.51 |
| mHealth | 4.10 | 2.78 | 4.75 | 2.37 |
| In person | 5.98 | 1.52 | 3.20 | 2.51 |
| Physical symptoms | ||||
| Full group | 3.85 | 1.72 | 2.78 | 2.13 |
| mHealth | 3.27 | 1.51 | 2.80 | 1.0 |
| In person | 4.34 | 1.64 | 2.76 | 2.93 |
| Distress | ||||
| Full group | 2.13 | 1.72 | 1.75 | 2.18 |
| mHealth | 1.70 | 1.26 | 1.23 | 1.21 |
| In person | 2.52 | 2.04 | 2.27 | 2.81 |
| Despair | ||||
| Full group | 1.24 | 1.48 | 0.95 | 1.71 |
| mHealth | 1.05 | 1.31 | 0.70 | 0.80 |
| In person | 1.43 | 1.66 | 1.21 | 2.32 |
Note. All comparisons were nonsignificant.